Aerie pharma accepts review of the roclanda marketing authorisation application in europe

Aerie pharmaceuticals announces acceptance for review of the roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% marketing authorisation application in europe.aerie pharmaceuticals - opinion from ema's committee for medicinal products for human use on maa for roclanda is expected in late 2020.aerie pharmaceuticals - expect to complete & analyze mercury 3 study in h2 2020.
AERI Ratings Summary
AERI Quant Ranking